Packaging product of micronutrient supplement for promoting digestive function of intestinal tract of body

Abstract

The present invention provides a package of a micronutrient supplement for promoting the digestive function of the intestinal tract of a body, the micronutrient supplement consisting of two types of unit dosage forms in one package for sale to a purchaser wherein the first type of unit dosage form contains VB6 and a compound thereof, and the second type of unit dosage form contains VB6 and a compound thereof. The first type of unit dosage form contains Zn and compounds thereof, the second type of unit dosage form contains Zn and compounds thereof or VD and compounds thereof, and the first type of unit dosage form does not contain Zn and VD, and the second type of unit dosage form does not contain VB6, the micronutrient supplement being provided in a manner of administration twice a day, the first type of unit dosage form is taken in an awakening period, and the second type of unit dosage form is taken in a sleep period. The packaging product can be matched with the biological clock rhythm of an organism, the absorption and utilization rate of micronutrients is increased, and then the intestinal digestion function is improved.

Description

Technical Field

[0001] This invention relates to the technical field of micronutrient supplementation, specifically to a packaged micronutrient supplement that promotes intestinal digestion. Background Technology

[0002] Micronutrients include vitamins (such as vitamins A, B complex, C, and D) and minerals (such as calcium, magnesium, selenium, and zinc). Although they constitute a small percentage of the body's composition, they play a crucial role in regulating digestive function and nutrient absorption. Vitamin B6 (VB6), a water-soluble vitamin, can influence digestive function by participating in amino acid metabolism. Its active form, pyridoxal phosphate, can promote the synthesis of gastrointestinal hormones, thereby enhancing gastrointestinal motility. Zinc (Zn), a mineral, serves as a component or activator of many digestive enzymes, improving the efficiency of food breakdown and absorption. Vitamin D (VD), a fat-soluble vitamin, can help break down fat-soluble components in food and improve nutrient absorption efficiency by regulating the activity of digestive enzymes in the intestines. These three micronutrients have a significant effect on promoting the body's digestive function.

[0003] The body's biological clock rhythm is generally divided into two phases: a human day consists of a sleep-wake period, while a mouse day consists of a resting-active period. Gastrointestinal activity varies throughout the day, with activity being more vigorous during wakefulness than during sleep. This results in a diurnal difference in the body's absorption and utilization efficiency of micronutrients. However, many micronutrient supplements currently on the market have the following drawbacks: they are mostly compound formulas, specifying only the dosage without specific time requirements for intake, failing to fully match the body's physiological rhythms, thus limiting the efficiency of micronutrient absorption and utilization and hindering their ability to maximize digestive benefits; some compound supplements contain nutrient components that interfere with absorption, and this problem is not avoided through appropriate dosage forms or methods of administration, further reducing the supplement's effectiveness; and micronutrient supplements specifically designed for intestinal digestion lack precise supplementation plans that align with the body's biological clock rhythms, failing to meet the digestive function improvement needs of specific populations.

[0004] Therefore, developing a micronutrient supplementation method that aligns with the body's circadian rhythm, avoids nutrient absorption antagonism, and precisely improves intestinal digestive function has become a pressing technical problem to be solved in this field. Summary of the Invention

[0005] The present invention aims to at least partially solve one of the technical problems in the above-mentioned technology, namely, to provide a packaged micronutrient supplement that promotes the digestive function of the body’s intestines. This packaged product can match the body’s biological clock rhythm, improve the absorption and utilization rate of micronutrients, and thus improve intestinal digestive function.

[0006] Therefore, in a first aspect of the invention, the invention provides a packaged micronutrient supplement that promotes intestinal digestion, the micronutrient supplement comprising two types of unit dosage forms in a package sold to a purchaser, wherein a first type of unit dosage form contains VB6 and its compounds, and a second type of unit dosage form contains Zn and its compounds or VD and its compounds, and the first type of unit dosage form does not contain Zn and VD, and the second type of unit dosage form does not contain VB6, the micronutrient supplement being administered twice daily, morning and evening, with the first type of unit dosage form taken during waking hours and the second type of unit dosage form taken during sleep hours.

[0007] According to the present invention, the packaged micronutrient supplement for promoting intestinal digestion function, in mouse animal experiments, for VB6, VB6 supplementation increased the small intestinal propulsion rate, digestive enzyme activity and gastrointestinal hormone levels, and jejunal villus height in mice; compared with VB6 supplementation during the resting period (sleep period), VB6 supplementation during the active period (wake period) showed better performance in the above indicators; for Zn, Zn supplementation increased the small intestinal propulsion rate, digestive enzyme activity and gastrointestinal hormone levels, and jejunal villus height in mice; compared with Zn supplementation during the active period, Zn supplementation during the resting period showed better performance in the above indicators; for VD, VD supplementation increased digestive enzyme activity; compared with VD supplementation during the resting period, VD supplementation during the active period showed better performance in the above indicators.

[0008] Therefore, this packaged product is designed with independent unit dosage forms for time-segmented supplementation based on the body's biological clock rhythm. VB6, Zn, and VD are classified into different unit dosage forms and matched with their respective optimal absorption periods. Time-segmented supplementation of micronutrients, such as supplementing VB6 during the waking period and supplementing Zn or VD during the sleeping period, has a significant effect on promoting digestion. p <0.05); This avoids the absorption antagonism that may occur when different nutrients are taken together, and conforms to the body's absorption patterns of various micronutrients. Experiments have verified that its improvement effect on digestion-related indicators (small intestinal propulsion rate, digestive enzyme activity, etc.) is statistically significant. p <0.05), significantly improving the efficiency of nutrient absorption and utilization.

[0009] Optionally, in the packaged product, the dosage of each of the VB6 and its compounds is 20-70 mg / kg, the dosage of each of the Zn and its compounds is 2-12 mg / kg, and the dosage of each of the VD and its compounds is 0.02-0.08 mg / kg.

[0010] Optionally, the dosage forms of the first type of unit dosage form and the second type of unit dosage form are any one of tablets, capsules, or gummies.

[0011] Furthermore, the dosage forms of the first type of unit dosage form and the second type of unit dosage form are different, or the first type of unit dosage form and the second type of unit dosage form are distinguished by color codes.

[0012] Optionally, the ratio of the first type of unit dosage form to the second type of unit dosage form in the packaged product is 1:1.

[0013] Optionally, the first type of unit dosage form is taken at the start of the waking period, and the second type of unit dosage form is taken at the start of the sleep period.

[0014] In a second aspect of the invention, a kit for a micronutrient supplement that promotes intestinal digestion is provided. The kit includes packaging containing two types of unit dosage forms and instructions for use. The first type of unit dosage form is a micronutrient supplement containing VB6 and its compounds, and the second type of unit dosage form is a micronutrient supplement containing Zn and its compounds or containing VD and its compounds. The first type of unit dosage form does not contain Zn or VD, and the second type of unit dosage form does not contain VB6. The ratio of the two types of unit dosage forms is 1:1. The micronutrient supplement is administered twice daily, morning and evening, with the first type of unit dosage form taken during wakefulness and the second type of unit dosage form taken during sleep. The instructions for use specify the recommended times and corresponding dosages of the first and second type of unit dosage forms per day.

[0015] Optionally, in the packaged product, the dosage of each of the VB6 and its compounds is 20-70 mg / kg, the dosage of each of the Zn and its compounds is 2-12 mg / kg, and the dosage of each of the VD and its compounds is 0.02-0.08 mg / kg.

[0016] Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. Attached Figure Description

[0017] Figure 1To illustrate the effect of different time points on VB6 or Zn supplementation on small intestinal propulsion rate in mice, the vertical axis of the figure represents small intestinal propulsion rate (the ratio of ink length to small intestinal length). A represents the effect of different time points on VB6 intake on small intestinal propulsion rate, and B represents the effect of different time points on Zn intake on small intestinal propulsion rate (n = 5, bar, ±SD). The Cont group consisted of mice on a normal diet, the VB6-ZT0 group consisted of mice supplemented with VB6 during the resting period, and the VB6-ZT12 group consisted of mice supplemented with VB6 during the active period. Similarly, the Con group consisted of mice on a normal diet, the Zn-ZT0 group consisted of mice supplemented with Zn during the resting period, and the Zn-ZT12 group consisted of mice supplemented with Zn during the active period. Figure 2 The effects of different time-dependent VB6 or Zn supplementation on the activity of digestive enzymes in the mouse intestine are shown in the figure. The vertical axis represents the activity of digestive enzymes. Among them, A represents the effect of different VB6 intake times on mouse α-amylase; B represents the effect of different VB6 intake times on mouse lipase; C represents the effect of different VB6 intake times on mouse trypsin; D represents the effect of different Zn intake times on mouse α-amylase; E represents the effect of different Zn intake times on mouse lipase; and F represents the effect of different Zn intake times on mouse trypsin (n = 5, bar, ±SD). The Cont group consisted of mice on a normal diet, the VB6-ZT0 group consisted of mice supplemented with VB6 during the resting period, and the VB6-ZT12 group consisted of mice supplemented with VB6 during the active period. The Con group consisted of mice on a normal diet, the Zn-ZT0 group consisted of mice supplemented with Zn during the resting period, and the Zn-ZT12 group consisted of mice supplemented with Zn during the active period. Figure 3 The effects of different time-dependent VB6 or Zn supplementation on gastrointestinal hormone levels in mice were shown in the figure. The vertical axis represents gastrointestinal hormone levels. A represents the effect of different VB6 intake times on motilin in mice; B represents the effect of different VB6 intake times on vasoactive intestinal peptide in mice; C represents the effect of different Zn intake times on cholecystokinin in mice; and D represents the effect of different Zn intake times on motilin in mice (n = 5, bar, ±SD). The Cont group consisted of mice on a normal diet, the VB6-ZT0 group consisted of mice supplemented with VB6 during the resting period, and the VB6-ZT12 group consisted of mice supplemented with VB6 during the active period. The Con group consisted of mice on a normal diet, the Zn-ZT0 group consisted of mice supplemented with Zn during the resting period, and the Zn-ZT12 group consisted of mice supplemented with Zn during the active period. Figure 4 The morphology of jejunal tissue in each group of mice was compared (H&E staining, ×300); where A and D were mice on a normal diet; B was mice that ingested VB6 during the resting period; C was mice that ingested VB6 during the active period; E was mice that ingested Zn during the resting period; and F was mice that ingested Zn during the active period. Figure 5The effect of VD3 supplementation at different times on the activity of digestive enzymes in the mouse intestine; the vertical axis in the figure represents the activity of digestive enzymes, where A is the effect of VD3 intake time on mouse α-amylase; B is the effect of VD3 intake time on mouse lipase; C is the effect of VD3 intake time on mouse trypsin; (n=5, bar, ±SD); the ND group is mice on a normal diet, the HFD group is mice on a high-fat diet, the VD3-ZT0 group is mice supplemented with VD3 during the resting period, and the VD3-ZT12 group is mice supplemented with VD3 during the active period. Detailed Implementation

[0018] The technical solution of the present invention is illustrated below through specific examples. It should be understood that the one or more method steps mentioned in the present invention do not preclude the existence of other method steps before or after the combined steps, or the insertion of other method steps between these explicitly mentioned steps; it should also be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the present invention. Furthermore, unless otherwise stated, the numbering of each method step is merely a convenient tool for identifying each method step, and not for limiting the order of the method steps or defining the scope of the present invention. Changes or adjustments to their relative relationships, without substantially altering the technical content, should also be considered within the scope of the present invention.

[0019] To better understand the above technical solutions, exemplary embodiments of the present invention are described in more detail below. While exemplary embodiments of the present invention are shown, it should be understood that the present invention may be implemented in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided to enable a more thorough understanding of the present invention and to fully convey the scope of the invention to those skilled in the art.

[0020] The test materials used in this invention are all common commercial products, which can be purchased on the market or prepared by known methods.

[0021] All experimental mice in this invention were housed under specific pathogen-free conditions, with alternating 12-hour light and 12-hour dark cycles, and the temperature controlled between 23°C and 26°C. Bedding was changed at least weekly, and maintenance feed was provided. Newly purchased mice were allowed one week to acclimatize to this environment before being used in experiments. To better differentiate between groups, the concept of zeitgeber time (ZT) was introduced. Zeitgeber time is a unit of time determined based on external zeitgeber factors (such as light, temperature, and feeding) and is used to synchronize the organism's internal rhythms with the external environmental cycle. The time the animal room lights were on was designated as ZT0, and the time the lights were off was designated as ZT12. All experimental mice involved in this application enjoyed due animal welfare, and all animal experiments in this application complied with animal ethics.

[0022] It should be noted that wakefulness and sleep are two distinct brain states widely present in humans, exhibiting clear circadian rhythms. Wakefulness refers to the dynamic process by which the body learns, works, expresses emotions, moves, and consciously recognizes and adapts to changes in environmental factors. Sleep is a normal physiological process and a necessary means to maintain life. Therefore, wakefulness-sleep is a dynamic physiological rhythm, and the time-segmented supplement proposed in this application utilizes this characteristic to precisely supplement the body with micronutrients at specific times, thereby achieving precise and efficient promotion of intestinal digestive function.

[0023] The present invention will now be described with reference to specific embodiments. It should be noted that these embodiments are merely descriptive and do not limit the present invention in any way.

[0024] Example 1: Effects of VB6 or Zn supplementation at different times on digestive function in young mice 1. Grouping and Drug Administration: Mice were randomly assigned to six groups: a control group (Cont and Con), a group supplemented with VB6 during the resting period (VB6-ZT0), a group supplemented with VB6 during the active period (VB6-ZT12), a group supplemented with Zn during the resting period (Zn-ZT0), and a group supplemented with Zn during the active period (Zn-ZT12), with 5 mice in each group. The resting period for mice was from 7:00 to 19:00 (ZT0), and the active period for mice was from 19:00 to 7:00 (ZT12).

[0025] 2. Sample Collection: The peritoneal cavity of mice was opened, and a portion of the small intestine was removed. The propulsion rate of the small intestine was measured. The H&E stained portion was fixed with 4% tissue fixative, and the portion detected by ELISA was stored at -80 ℃ for later use.

[0026] 3. Small intestinal propulsion rate test: Take out a complete small intestine of the mouse, and use a ruler to measure the total length of the small intestine and the distance the toner moves in the small intestine. Calculate the small intestinal propulsion rate by the ratio of these two lengths.

[0027] The results are as follows Figure 1 As shown, compared with the control group, the small intestinal propulsion rate of mice in both VB6 intake groups was significantly increased. Although there was no significant difference between the two VB6 intake groups, the small intestinal propulsion rate of the VB6-ZT12 group was slightly higher than that of the VB6-ZT0 group.

[0028] Compared with the control group, the small intestinal propulsion rate of the Zn-ZT0 group was significantly increased, while the Zn-ZT12 group also showed an increase, but there was no significant difference. Therefore, the Zn-ZT12 group had a slightly greater effect on the small intestinal propulsion rate of mice than the Zn-ZT0 group.

[0029] 4. The activity of digestive enzymes and the level of gastrointestinal hormones in the mouse intestine were detected by ELISA: Small intestinal tissues of mice in each group were taken and samples were prepared according to the ELISA kit instructions. The levels of α-amylase, lipase, trypsin, cholecystokinin (CCK), motilin (MTL), and vasoactive intestinal peptide (VIP) were detected.

[0030] The results are as follows Figure 2 , Figure 3 As shown, compared with the control group, the VB6-ZT12 group significantly increased the activities of α-amylase, lipase, and trypsin, while the VB6-ZT0 group significantly increased lipase activity. Both VB6 intake groups increased the activities of the three digestive enzymes, but the effect of the VB6-ZT12 group was superior to that of the VB6-ZT0 group. Compared with the control group, both VB6 intake groups significantly increased the level of motilin and decreased the level of vasoactive intestinal peptide. However, the improvement effect of the VB6-ZT12 group was superior to that of the VB6-ZT0 group.

[0031] Compared with the control group, the Zn-ZT0 group significantly increased the activities of α-amylase, lipase, and trypsin, while the Zn-ZT12 group significantly increased the activities of α-amylase and lipase. Both Zn intake groups increased the activities of the three digestive enzymes, but the Zn-ZT0 group was more effective than the Zn-ZT12 group. Compared with the control group, the Zn-ZT0 group significantly increased the levels of cholecystokinin (CCK) and motilin (MTL), while the Zn-ZT12 group significantly increased the level of motilin (MTL). Therefore, the Zn-ZT0 group showed a better improvement than the Zn-ZT12 group.

[0032] 5. Observe the morphology of mouse jejunal tissue using H&E staining: After fixing the jejunal tissue, it was dehydrated by gradient (50% → 60% → 70% → 80% → 90% → 95% → 100%) ethanol, embedded and sectioned, stained with hematoxylin and eosin, and the morphology of mouse jejunal tissue in each group was observed under a fluorescence inverted microscope.

[0033] H&E staining, such as Figure 4 As shown, the mice in the control group and the two VB6 intake groups had intact tissue structures, smooth villi surfaces, clear morphology, neatly arranged goblet cells, and no glandular atrophy was observed in the lamina propria. Compared with the VB6-ZT0 group, the VB6-ZT12 group significantly increased villi height and increased the nutrient absorption area.

[0034] The mice in the control group and the two Zn intake groups had intact tissue structures, smooth villi surfaces, clear morphology, neatly arranged goblet cells, and no glandular atrophy was observed in the lamina propria. Compared with the Zn-ZT12 group, the Zn-ZT0 group significantly increased villi height and increased the nutrient absorption area.

[0035] Example 2: Effects of Vitamin D3 supplementation at different times on digestive function in adult overweight mice 1. Grouping and Drug Administration: The experiment consisted of two phases: the first phase was the overweight mouse modeling phase, and the second phase was the VD3 intake phase. In the first phase, mice were divided into a normal diet group (ND) and a high-fat diet group (HFD). After successful modeling, the HFD group was further divided into three subgroups: the HFD group, the resting-phase VD3 intake group (VD3-ZT0), and the active-phase VD3 intake group (VD3-ZT12), with five mice in each subgroup. During the experiment, the ND group was given a maintenance diet throughout, while the HFD group, VD3-ZT0 group, and VD3-ZT12 group were given a high-fat diet throughout.

[0036] 2. Detection of intestinal digestive enzyme activity in mice using ELISA: Small intestinal tissues from mice in each group were collected and samples were prepared according to the ELISA kit instructions. The activities of α-amylase, lipase, and trypsin were then detected.

[0037] The results are as follows Figure 5 As shown, compared with the ND group mice, the VD3 intake group increased the activity of three digestive enzymes, but the effect of the VD3-ZT0 group was better than that of the VD3-ZT12 group.

[0038] In summary, according to embodiments of the present invention, supplementation with VB6 during the active phase and Zn during the resting phase can improve the digestive function of mice by increasing small intestinal propulsion rate, improving digestive enzyme activity and gastrointestinal hormone levels, and increasing jejunal villus height. Supplementation with VD3 during the resting phase can improve the digestive function of mice by increasing digestive enzyme activity. Therefore, supplementation with VB6 during the active phase and Zn or VD3 during the resting phase improves the absorption and utilization efficiency of the three micronutrients in mice, thereby improving their digestive function.

[0039] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the invention. The illustrative expressions of the above terms in this specification should not be construed as necessarily referring to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. In addition, those skilled in the art can combine and integrate the different embodiments or examples described in this specification.

[0040] Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention.

Claims

1. A package of a micronutrient supplement for promoting the digestive function of the intestinal tract of a body, characterized by comprising: The micronutrient supplement is sold to the purchaser in a package consisting of two types of unit dosage forms, wherein the first type of unit dosage form contains VB6 and its compounds, and the second type of unit dosage form contains Zn and its compounds or VD and its compounds. The first type of unit dosage form does not contain Zn and VD, and the second type of unit dosage form does not contain VB6. The micronutrient supplement is provided in a morning and evening administration manner, with the first type of unit dosage form taken during the waking period and the second type of unit dosage form taken during the sleeping period.

2. The packaging article as described in claim 1, characterized in that, In the packaged product, the dosage of each of the VB6 and its compounds is 20-70 mg / kg, the dosage of each of the Zn and its compounds is 2-12 mg / kg, and the dosage of each of the VD and its compounds is 0.02-0.08 mg / kg.

3. The packaging article as described in claim 1, characterized in that, The dosage forms of the first type of unit dosage form and the second type of unit dosage form are any one of tablets, capsules or gummies; the first type of unit dosage form and the second type of unit dosage form are distinguished by color markings; the ratio of the first type of unit dosage form to the second type of unit dosage form in the packaged product is 1:

1.

4. The packaging article as described in claim 1, characterized in that, The first type of unit dosage form is taken at the start of the waking period, and the second type of unit dosage form is taken at the start of the sleep period.

5. A kit for a micronutrient supplement that promotes intestinal digestion, characterized in that, The kit includes packaging containing two types of unit dosage forms and instructions for use. The first type of unit dosage form is a micronutrient supplement containing VB6 and its compounds, and the second type of unit dosage form is a micronutrient supplement containing Zn and its compounds or containing VD and its compounds. The first type of unit dosage form does not contain Zn or VD, and the second type of unit dosage form does not contain VB6. The ratio of the two types of unit dosage forms is 1:

1. The micronutrient supplements are administered twice daily, morning and evening, with the first type of unit dosage form taken during wakefulness and the second type of unit dosage form taken during sleep. The instructions for use specify the recommended times and corresponding doses of the first and second type of unit dosage forms per day. In the packaging, the dosage of each VB6 and its compound is 20–70 mg / kg, the dosage of each Zn and its compound is 2–12 mg / kg, and the dosage of each VD and its compound is 0.02–0.08 mg / kg.

Images